Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Depreciation and Depletion (2015 - 2017)

Intellia Therapeutics (NTLA) reported Depreciation and Depletion of $660000.0 for Q1 2017, up 252.94% year-over-year from $187000.0 in Q1 2016, and up 64.59% on a QoQ basis from $401000.0 in Q4 2016.

Intellia Therapeutics (NTLA) has 3 years of Depreciation and Depletion data on file, last reported at $660000.0 in Q1 2017.

  • Quarterly Depreciation and Depletion rose 252.94% year-over-year to $660000.0 in Q1 2017, while the trailing twelve-month figure through Mar 2017 was $1.6 million (up 246.48% YoY) and the FY2017 annual result came in at $3.0 million, up 172.73% from the prior year.
  • Depreciation and Depletion grew to $660000.0 in Q1 2017 per NTLA's latest filing, from $401000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $660000.0 in Q1 2017 and bottomed at $33000.0 in Q1 2015.
  • The 3-year median for Depreciation and Depletion is $187000.0 (2016), against an average of $228888.9.
  • Peak annual rise in Depreciation and Depletion reached 466.67% in 2016, while the deepest fall reached 176.04% in 2016.
  • Tracing NTLA's Depreciation and Depletion over 3 years: stood at $104000.0 in 2015, then surged by 285.58% to $401000.0 in 2016, then soared by 64.59% to $660000.0 in 2017.
  • Per Business Quant, the three latest NTLA Depreciation and Depletion figures stand at $660000.0 (Q1 2017), $401000.0 (Q4 2016), and $265000.0 (Q3 2016).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation and Depletion (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 1,395.22
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Intellia Therapeutics 1.63 Bn 1.63 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2017 660,000.00
Mar 31, 2017 660,000.00
Dec 31, 2016 401,000.00
Dec 31, 2016 401,000.00
Sep 30, 2016 265,000.00
Sep 30, 2016 265,000.00
Jun 30, 2016 247,000.00
Jun 30, 2016 247,000.00
Mar 31, 2016 187,000.00
Mar 31, 2016 187,000.00
Dec 31, 2015 104,000.00
Dec 31, 2015 104,000.00
Sep 30, 2015 96,000.00
Sep 30, 2015 96,000.00
Jun 30, 2015 67,000.00
Jun 30, 2015 67,000.00
Mar 31, 2015 33,000.00
Mar 31, 2015 33,000.00